AN2 Therapeutics Initiates Phase 2 Trial of Epetraborole for Difficult-to-Treat M. abscessus Lung Disease AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies using its…
AN2 Therapeutics, Inc. Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapeutics…
AN2 Therapeutics Reports Phase 3 Data from EBO-301 Trial and Details Strategic Pipeline Advancements Across Boron Chemistry Platform AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company pioneering boron-based small…
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company specializing in novel small molecule therapies from its boron chemistry platform, today announced topline results from the Phase 2 portion of the…